Intellia Initiates Rolling BLA Submission for In Vivo CRISPR Therapy in Hereditary Angioedema
Big Molecule Watch
On April 27, 2026, Intellia Therapeutics ("Intellia") announced that it has begun a rolling submission of a biologics license application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z), an inves
pharminent
April 28, 2026 (Last updated: April 29, 2026)
Big Molecule Watch
On April 27, 2026, Intellia Therapeutics (“Intellia”) announced that it has begun a rolling submission of a biologics license application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z), an inves
